8-K: Wellgistics Health Licenses AI Blockchain for Pharma Distribution

Wellgistics Health secures an exclusive license from DataVault AI to develop blockchain-enabled smart contracts for the prescription drug industry, aiming to disrupt distribution and reduce costs.

Summary

• Wellgistics Health, Inc. (WGRX) entered into an exclusive license agreement with DataVault AI Inc. (DVLT) on November 24, 2025.
• The agreement grants Wellgistics access to DataVault's intellectual property for developing "PharmacyChain," a manufacturer-to-patient blockchain-enabled smart contract system designed to optimize prescription drug distribution.
• Wellgistics will pay a non-refundable license fee of $2,500,000 to DataVault by December 31, 2025.
• A royalty fee of 13% on all net profit received by Wellgistics from the use of the license will be paid monthly to DataVault.
• A minimum annual royalty of $1,000,000 will be due to DataVault for the calendar year 2028 and each year thereafter, with a condition for 2028 and 2029 that Wellgistics must achieve at least $2,000,000 in annual net profit from PharmacyChain for the minimum to apply.
• Wellgistics has the right to sublicense the licensed materials and agrees to remit 90% of all net revenue received from such sublicenses to DataVault quarterly.
• The initiative aims to fully digitize prescription drug tracking, integrate with Wellgistics' EinsteinRx artificial intelligence hub, and optimize fulfillment across the $634 billion US prescription drug industry.

Sentiment

Score: 7

Explanation: The filing announces a significant strategic move with high potential for disruption and growth in a large market, backed by exclusive IP and AI integration. However, it involves substantial financial commitments and inherent execution risks associated with new technology adoption and challenging established industry practices.

Positives

• Secured an exclusive license for critical intellectual property enabling blockchain-enabled smart contracts for pharmaceutical distribution, providing a 'smart contracts barrier to entry' in the $4.9 trillion US healthcare market.
• Positions Wellgistics Health to become a leader in Web 3.0 health information data transfer within the $634 billion US prescription drug industry.
• Aims to significantly disrupt the prescription drug industry by optimizing tracking, dispensing, and insurance coverage from manufacturer to patient.
• Implementation of Wellgistics' proprietary EinsteinRx artificial intelligence hub will facilitate automated prescription fulfillment optimization for various stakeholders.
• Potential to minimize or eliminate Pharmacy Benefit Manager (PBM) rebates for pharmacies and manufacturers, while reducing administrative burden for payers.
• Empowers patients with the ability to monetize their health data, potentially leading to reduced out-of-pocket costs.
• The effort is now backed by defensible intellectual property, which is expected to accelerate integration of EinsteinRx and the creation of an optimal blockchain protocol.

Negatives

• Requires a substantial non-refundable license fee of $2,500,000 to be paid by December 31, 2025.
• Wellgistics Health is committed to ongoing royalty payments of 13% on all net profit generated from the use of the license.
• A minimum annual royalty of $1,000,000 is mandated starting in 2028, which could be a financial burden if PharmacyChain adoption is slower than expected, even with the conditional waiver for 2028-2029.
• 90% of net revenue from any sublicenses granted must be remitted to DataVault, limiting Wellgistics' direct upside from such arrangements.
• The success of PharmacyChain is dependent on successful development, integration, and widespread adoption within a complex and highly regulated industry.

Risks

• Forward-looking statements regarding projects, potential financial performance, and growth opportunities are subject to inherent risks and uncertainties.
• Actual results, performance, or achievements could differ materially from those expressed or implied by forward-looking statements due to various factors.
• Unanticipated factors could arise that impact the success or financial outcomes of the PharmacyChain initiative.
• The company's ability to successfully develop, integrate, and achieve market adoption for its blockchain-enabled smart contract platform (PharmacyChain) is crucial for realizing the anticipated benefits.
• Significant financial commitments, including the $2,500,000 license fee and ongoing royalties, pose a financial risk if the project does not generate sufficient revenue or profit.
• Risks related to the company's forward-looking statements are extensively discussed in its Registration Statement on Form S-1, declared effective September 25, 2025.

Future Outlook

Wellgistics Health anticipates becoming the leading smart contract-enabled pharmaceutical distribution platform in the country by integrating its EinsteinRx AI hub with the PharmacyChain blockchain platform. The company expects to attract employers, HMOs, and other payers by offering greater visibility and transparency, aiming to reduce costs for payers, improve patient outcomes, and provide better data to manufacturers. The goal is to disrupt and improve prescription drug dispensing in the U.S. by minimizing or eliminating PBM rebates and reducing administrative burdens, and to empower patients to monetize their data.

Management Comments

• "This license agreement puts DataVault AI's proprietary intellectual property enables Wellgistics AI to significantly disrupt the $634 billion US prescription drug industry." Nathaniel Bradley, President & CEO of DataVault AI.
• "Web 3.0 smart contracts are the future of secure data transfer that allow for the automation of key functions to more quickly close loops that leave tasks open that slow down the conduct of the business in the $4.9 trillion healthcare industry." Nathaniel Bradley, President & CEO of DataVault AI.
• "We see the potential for significant improvement in the cost and efficiency of filling prescriptions that will reduce costs for payers while improving outcomes for patients and giving better data to the manufacturer." Nathaniel Bradley, President & CEO of DataVault AI.
• "Now that we have completed EinsteinRd, we are poised to put it on the PharmacyChain blockhchain-enabled smart contract platform and become the leading smart contract-enabled pharmaceutical distribution platform in the country." Prashant Patel, RPh, President & Interim-CEO of Wellgistics.
• "With defensible IP now backing our effort, we will accelerate our efforts to integrate EinsteinRx into our customers workflow and work through the various steps to ensure the creation of an optimal blockchain protocol that we expect to become the standard in the commercial prescription drug distribution industry." Prashant Patel, RPh, President & Interim-CEO of Wellgistics.
• "By minimizing or eliminating PBM rebates for pharmacies and manufacturers while reducing administrative burden for payers, Wellgistics intends to disrupt and improve the path through which prescription drugs are dispensed in the United States." Prashant Patel, RPh, President & Interim-CEO of Wellgistics.
• "Given our CTO Srini Kallas background at OptumRX, we intend to find new ways to reduce out-of-pocket costs by empowering patients with the ability to monetize their data to manufacturers or other stakeholders within the healthcare system." Prashant Patel, RPh, President & Interim-CEO of Wellgistics.

Industry Context

This strategic partnership leverages emerging technologies like AI and blockchain to address inefficiencies and high costs within the massive US healthcare and prescription drug markets, valued at $4.9 trillion and $634 billion respectively. It aligns with broader industry trends towards digital transformation, data transparency, and patient empowerment, aiming to capture a share of the estimated $1 trillion opportunity identified by PwC for shifting healthcare spending towards a digital-first, proactive system. The move positions Wellgistics to compete by offering a more streamlined and transparent alternative to traditional pharmaceutical distribution models, particularly by challenging the role of Pharmacy Benefit Managers (PBMs).

Comparison to Industry Standards

• The initiative aims to disrupt the existing $634 billion US prescription drug industry by introducing blockchain-enabled smart contracts, a novel approach to traditional distribution models.
• Wellgistics' strategy to minimize or eliminate PBM rebates for pharmacies and manufacturers directly challenges the established practices of major PBMs like OptumRx (where Wellgistics' CTO previously worked), CVS Caremark, and Express Scripts, which currently play a significant role in drug pricing and rebates.
• The focus on empowering patients to monetize their data represents an innovative approach compared to current industry standards where patient data is often aggregated and utilized without direct patient benefit.
• The integration of AI (EinsteinRx) with blockchain (PharmacyChain) positions Wellgistics at the forefront of technological adoption in healthcare, aiming to create a new standard for secure and efficient data transfer, contrasting with fragmented and less transparent legacy systems.
• The company's goal to become the 'Web 3.0 Health Information Data Transfer Leader' and establish an 'optimal blockchain protocol that we expect to become the standard' indicates an ambition to set new benchmarks for the industry rather than merely conforming to existing ones.

Stakeholder Impact

• Shareholders: Potential for significant long-term value creation through market disruption and growth, but also exposed to substantial upfront costs, ongoing royalty obligations, and execution risks of a complex technological and business model transformation.
• Manufacturers: Expected to benefit from improved data visibility, transparency, and potentially reduced PBM rebates, leading to more efficient distribution channels.
• Pharmacies (Wellgistics' network of 6,500+ independent pharmacies): Anticipated to experience optimized prescription fulfillment, reduced administrative burden, and potentially higher profitability by minimizing PBM rebates.
• Physicians: Will have access to more comprehensive and accurate patient data, enabling better-informed healthcare decisions.
• Patients: Expected to receive the right medication at the right time with appropriate recommendations, potentially lower out-of-pocket costs, and the ability to monetize their health data.
• Payers (Employers, HMOs): Anticipated to benefit from greater visibility, transparency, and reduced costs associated with prescription drug fulfillment by bypassing traditional PBM structures.
• DataVault AI Inc.: Will receive a significant non-refundable license fee, ongoing royalties, and a share of sublicense revenue, benefiting from the commercialization of its intellectual property.

Next Steps

• Accelerate efforts to integrate EinsteinRx into customer workflows.
• Work through various steps to ensure the creation of an optimal blockchain protocol.
• Aim for the blockchain protocol to become the standard in the commercial prescription drug distribution industry.
• Find new ways to reduce out-of-pocket costs by empowering patients to monetize their data to manufacturers or other stakeholders within the healthcare system.

Key Dates

Keywords

blockchain, smart contracts, prescription drugs, pharmaceutical distribution, healthcare technology, AI, intellectual property, licensing, PharmacyChain, EinsteinRx, Web 3.0, data monetization, PBMs